Clinical Trials Logo
  1. Home
  2. HIV I Infection
  3. NCT03622177

Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection

HIV I Infection Clinical Trial

Official title:
Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection : a Prospective Cross-sectional Observational Study

Clinical Trial Summary

Interleukin33 organize local immune reactions, especially at epithelial barriers.

ST2 is the IL33 receptor. The sST2 rate is higher for patient living with HIV and is an independent predictable factor of mortality. Interleukin33 induce tissue Treg ST2+ lymphocytes proliferation and amphireguline production. Amphireguline is member of epithelial growth factors family, which contributes to tissue repair, and fibrose. Amphireguline also helps immunosuppressives functions. Targetting amphiregulin for people living with HIV who has poor restauration of LTCD4+ could be a future therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03622177
Study type Observational
Source French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Contact
Status Not yet recruiting
Phase
Start date September 2018
Completion date September 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04585737 - Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF Phase 4
Not yet recruiting NCT06282783 - Studying Topiramate for Re-Activating the HIV-1 Reservoir Phase 1/Phase 2
Recruiting NCT05854381 - To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV Phase 1
Enrolling by invitation NCT05071378 - Leveraging Family-Based Assets for Black MSM In House Ball Communities N/A
Completed NCT05421806 - A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
Completed NCT04568395 - Acute Effects of TCIG vs ECIG in PLWH N/A
Recruiting NCT04887675 - Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI N/A
Recruiting NCT04820933 - Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV Early Phase 1
Completed NCT03584048 - Charlotte Retention in Care Study
Recruiting NCT06005610 - Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy Phase 2
Recruiting NCT05947890 - Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa Phase 2
Recruiting NCT05187429 - Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy Phase 1/Phase 2
Active, not recruiting NCT05601128 - A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA Phase 3
Completed NCT04675255 - Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism N/A
Recruiting NCT05110963 - Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments N/A
Completed NCT03986099 - Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ART N/A
Completed NCT04971343 - Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
Completed NCT04725877 - VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers Phase 1
Recruiting NCT04618198 - Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa Phase 3
Completed NCT05383456 - The Visceral Adiposity Measurement and Observation Study